Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo responses and variability in Phase 2 trials but still promoted Phase 3 trial success. Shareholders who bought stock before April 1, 2024, are urged to contact the law firm to protect their rights. This case highlights potential governance issues affecting investor confidence in Vistagen Therapeutics.
As summer begins, North Texas faces a surge in child hunger due to loss of school meals. WFAA, North Texas Food Bank, and Tarrant Area Food Bank are hosting the Nourish North Texas Telethon on June 11 to raise funds for at least one million meals for...
AstraZeneca's Phase 3 EMERALD-3 trial demonstrated that the STRIDE regimen, combining immunotherapy drugs Imfinzi and Imjudo with lenvatinib and TACE, significantly improved progression-free survival by 30% compared to TACE alone in patients with unr...
Motorola Solutions announced the acquisition of D-Fend Solutions, a leader in counter-drone technology, for $1.5 billion. This move aims to enhance Motorola's airspace security capabilities amid rising drone threats. D-Fend has shown over 50% annual ...
Quadient has released the official notice and agenda for its Ordinary Annual and Extraordinary General Meeting scheduled for June 18, 2026. Key documents including draft resolutions and participation details are available on the company's website and...
Quadient has made available the preparatory documents for its Ordinary Annual and Extraordinary General Meeting scheduled for June 18, 2026. These documents, including the agenda and proposed resolutions by the Board of Directors, are accessible on Q...
